NeoGenomics, Inc. (NEO)

NeoGenomics, Inc. (NEO) is a healthcare company (diagnostics & research) based in the United States. The share price is $15.25, down 1.04% on the day, which values the company at $1.97B. Price as of 18 Nov 2026, 10:38 UTC, from Yahoo Finance.

Key facts

Share price
$15.25−1.04% today
Market value
$1.97B
Forward P/E
48.5×
Funk Score
44/100
Against its own history
Well below its usual priceusual price $29.07
200-week average
$13.3914% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

NeoGenomics, Inc. in more detail

NEO trades at 48.5× next year's expected earnings, 2.5× sales. Measured against its own history, the price is 48% below what its usual multiples would imply ($29.07) — well below its usual price. It sits 14% above its 200-week average of $13.39.

Over the last five fiscal years NeoGenomics, Inc. has compounded revenue 10.4% a year. Its Funk Score is 44 out of 100 (financial strength 2.7, profitability 2.6, growth 7.5, value 4.7, each out of 10).

In its favour: Operating margin is expanding; Five straight years of revenue growth. Worth checking: Share count keeps rising; Thin interest cover.

NeoGenomics, Inc. (NEO): questions and answers

What is NEO's PEG ratio?

NeoGenomics, Inc.'s PEG ratio is 2.09 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is NeoGenomics, Inc.'s market cap?

NeoGenomics, Inc. is valued at $1.97B at a share price of $15.25.

Is NEO overvalued or undervalued?

Against its own history, NEO is well below its usual price: the price is 48% below the $29.07 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is NEO above its 200-week moving average?

Yes. NEO is 13.9% above its 200-week average of $13.39. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is NeoGenomics, Inc. growing?

Over the last five fiscal years NeoGenomics, Inc.'s revenue grew 10.4% a year; over ten years revenue grew 64.5% a year.

Does NEO pay a dividend?

NeoGenomics, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “NeoGenomics, Inc. (NEO) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/NEO

Underlying data: Yahoo Finance; company filings with the SEC.